Engineering SF3B1 mutation into CLL cell lines necessitates an additional enrichment marker
No takes yet. Share an insight, caveat, or question.
Fernandez et al. (2024) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: